Comparing sotagliflozin to standard blood thinners for heart health
Part of Heart & circulation clinical trials.
This study compares how well a diabetes drug, sotagliflozin, affects blood clotting compared to common blood thinners like aspirin and clopidogrel. It may help people at risk for heart problems find a safer or more effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must not have Type 1 diabetes or a history of ketoacidosis.
- You must not be pregnant, planning to become pregnant, or breastfeeding.
- You must not have taken NSAIDs (like ibuprofen or naproxen) or aspirin in the last 7 days, or blood thinners in the last 10 days.
- You must weigh more than 60 kilograms (about 132 pounds).
- You must not have a history of alcohol abuse, pancreatitis, or a ketogenic diet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
Hear when a new Platelet Function and Reactivity Tests trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.